首页> 外文OA文献 >A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.
【2h】

A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.

机译:新一代逆转录病毒生产细胞:通过Flp介导的逆转录病毒载体的位点特异性整合,可预测和稳定地产生病毒。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We developed a new strategy that provides well-defined high-titer producer cells for recombinant retroviruses in a minimum amount of time. The strategy involves the targeted integration of the retroviral vector into a chromosomal locus with favorable properties. For proof of concept we established a novel HEK293-based retroviral producer cell line, called Flp293A, with a single-copy retroviral vector integrated at a selected chromosomal locus. The vector was flanked by noninteracting Flp-recombinase recognition sites and was exchanged for different retroviral vectors via Flp-mediated cassette exchange. All analyzed cell clones showed correct integration and identical titers for each of the vectors, confirming that the expression characteristics from the parental cell were preserved. Titers up to 2.5 x 10(7) infectious particles/10(6) cells were obtained. Also, high-titer producer cells for a therapeutic vector that encodes the 8.9-kb collagen VII cDNA in a marker-free cassette were obtained within 3 weeks without screening. Thus, we provide evidence that the precise integration of viral vectors into a favorable chromosomal locus leads to high and predictable virus production. This method is compatible with other retroviral vectors, including self-inactivating vectors and marker-free vectors. Further, it provides a tool for evaluation of different retroviral vector designs.
机译:我们开发了一种新策略,可在最短时间内为重组逆转录病毒提供定义明确的高滴度生产细胞。该策略涉及将逆转录病毒载体靶向整合到具有有利特性的染色体基因座中。为概念验证,我们建立了一种新型的基于HEK293的逆转录病毒生产细胞系,称为Flp293A,其单拷贝的逆转录病毒载体整合在选定的染色体位点上。该载体侧翼为非相互作用的Flp重组酶识别位点,并通过Flp介导的盒交换而交换为不同的逆转录病毒载体。所有分析的细胞克隆均显示正确的整合和每种载体的相同滴度,从而确认了亲代细胞的表达特征得以保留。获得最多2.5 x 10(7)感染颗粒/ 10(6)细胞的滴度。同样,无需筛选即可在3周内获得用于无标记盒中编码8.9-kb胶原VII cDNA的治疗载体的高滴度生产细胞。因此,我们提供的证据表明,将病毒载体精确整合到有利的染色体基因座中会导致病毒产生量高且可预测。该方法与其他逆转录病毒载体兼容,包括自我灭活载体和无标记载体。此外,它提供了用于评估不同逆转录病毒载体设计的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号